【原著論文】
Fujiwara K, Tsunei A, Kusabuka H, Ogaki E, Tachibana M, Okada N.
Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold.
Cells. 2020;9(5):E1182.

Fujiwara K, Shigematsu K, Tachibana M, Okada N.
Development and functional analysis of an anticancer T-cell medicine with immune checkpoint inhibitory ability.
IUBMB Life, 2020;72(8):1649-1658.

Fujiwara K, Masutani M, Tachibana M, Okada N.
Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties.
Biochem Biophys Res Commun. 2020;527(2):350-357.

Ito S, Hirobe S, Kawakita T, Saito M, Quan YS, Kamiyama F, Ishii KJ, Nagao M, Fujisawa T, Tachibana M, Okada N.
Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant.
Pharmaceutics. 2020;12(3):E267.

Tachibana M*,#, Watanabe N*, Koda Y*, Oya Y, Kaminuma O, Katayama K, Fan Z, Sakurai F, Kawabata K, Hiroi T#, Mizuguchi H#. (*contributed equally, #co-corresponding author)
Ablation of IL-17A leads to severe colitis in IL-10-deficient mice: implications of myeloid-derived suppressor cells and NO production.
Int Immunol. 2020;32(3):187-201.

Xie Z, Ikegami T, Ago Y, Okada N, Tachibana M. (corresponding author)
Valproic acid attenuates CCR2-dependent tumor infiltration of monocytic myeloid-derived suppressor cells, limiting tumor progression.
Oncoimmunology, 2020;9(1): 1734268.

 

【著書】
立花雅史
パルミチン酸による骨髄由来免疫抑制細胞分化阻害と抗がん免疫応答の活性化
アグリバイオ, 北隆館, 2020: 4(6), 71-3

立花雅史
パルミチン酸による骨髄由来免疫抑制細胞分化制御とがん治療への応用
Medical Science Digest, ニューサイエンス社, 2020: 46(3), 40-1

​